ROBIMYCIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Robimycin, and what generic alternatives are available?
Robimycin is a drug marketed by Robins Ah and is included in one NDA.
The generic ingredient in ROBIMYCIN is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Robimycin
A generic version of ROBIMYCIN was approved as erythromycin by TORRENT on July 6th, 2020.
Summary for ROBIMYCIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 103 |
Patent Applications: | 7,264 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ROBIMYCIN at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ROBIMYCIN
US Patents and Regulatory Information for ROBIMYCIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Robins Ah | ROBIMYCIN | erythromycin | TABLET, DELAYED RELEASE;ORAL | 061633-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |